Anodyne
- Biotech or pharma, therapeutic R&D
- Medical device or technology
- Other R&D services
Anodyne is a clinical-stage biotech company, based in Boston, converting IV & SC injections to transdermal premium products for the treatment of chronic diseases. Our proprietary technology enables the transdermal delivery of multi-milligram doses of large molecules (mAbs, peptides, LNPs).
The lead asset, ANN-101, is a once-weekly GLP1 patch for obesity. Phase I study to begin Q1 2026.
In addition to progressing our own pipeline, we are collaborating with biotech partners to tackle formulation, delivery and pharmacokinetic challenges, offering:
i) Tunable Pharmacokinetic Profiles
ii) Optimized Delivery of Biologics
iii) Room Temperature Stability
iv) Combination Therapies in a single patch
Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}